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Abstract
Background: Neurotrophin receptors were initially identified in neural cells. They were recently detected in some cancers in
association with invasiveness, but the function of these tyrosine kinase receptors was not previously investigated in
colorectal cancer (CRC) cells.
Methods and Findings: We report herein that human CRC cell lines synthesize the neural growth factor Brain-derived
neurotrophic factor (BDNF) under stress conditions (serum starvation). In parallel, CRC cells expressed high- (TrkB) and low-
affinity (p75
NTR) receptors at the plasma membrane, whereas TrkA and TrkC, two other high affinity receptors for NGF and
NT-3, respectively, were undetectable. We demonstrate that BDNF induced cell proliferation and had an anti-apoptotic
effect mediated through TrkB, as assessed by K252a, a Trk pharmacologic inhibitor. It suppressed both cell proliferation and
survival of CRC cells that do not express TrkA nor TrkC. In parallel to the increase of BDNF secretion, sortilin, a protein acting
as a neurotrophin transporter as well as a co-receptor for p75
NTR, was increased in the cytoplasm of primary and metastatic
CRC cells, which suggests that sortilin could regulate neurotrophin transport in these cells. However, pro-BDNF, also
detected in CRC cells, was co-expressed with p75
NTR at the cell membrane and co-localized with sortilin. In contrast to
BDNF, exogenous pro-BDNF induced CRC apoptosis, which suggests that a counterbalance mechanism is involved in the
control of CRC cell survival, through sortilin as the co-receptor for p75
NTR, the high affinity receptor for pro-neurotrophins.
Likewise, we show that BDNF and TrkB transcripts (and not p75
NTR) are overexpressed in the patients’ tumors by
comparison with their adjacent normal tissues, notably in advanced stages of CRC.
Conclusion: Taken together, these results highlight that BDNF and TrkB are essential for CRC cell growth and survival in
vitro and in tumors. This autocrine loop could be of major importance to define new targeted therapies.
Citation: Akil H, Perraud A, Me ´lin C, Jauberteau M-O, Mathonnet M (2011) Fine-Tuning Roles of Endogenous Brain-Derived Neurotrophic Factor, TrkB and Sortilin
in Colorectal Cancer Cell Survival. PLoS ONE 6(9): e25097. doi:10.1371/journal.pone.0025097
Editor: Mark P. Mattson, National Institute on Aging Intramural Research Program, United States of America
Received July 6, 2011; Accepted August 23, 2011; Published September 26, 2011
Copyright:  2011 Akil et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by Ligue contre le Cancer and Conseil Re ´gional du Limousin. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: m-o.jauberteau-marchan@unilim.fr
Introduction
Brain-derived neurotrophic factor (BDNF), a member of the
neurotrophin family, is known to play a critical role in the
modulation of cell survival, differentiation and apoptosis in the
nervous system [1].
BDNF signals through two types of cell surface receptors: the
high-affinity tropomyosin-related kinase (Trk) receptor B (TrkB), a
tyrosine kinase receptor and the low affinity receptor (p75
NTR), as
well as a death domain receptor belonging to the tumor necrosis
factor (TNF) receptor family, a common receptor for all
neurotrophins nerve growth factor (NGF), neurotrophin-3 (NT-
3), and neurotrophin-4/5 (NT-4/5). Neurotrophins are synthe-
sized as precursors (proneurotrophins) that are proteolytically
cleaved to mature neurotrophins. Pro-BDNF cleavage can occur
either intracellularly by the action of furin or proconvertase, or
extracellularly by the action of plasmin, matrix metalloproteinase
7 (MMP-7) or MMP-9 [2]. Both mature BDNF and pro-BDNF
are biologically active, with divergent roles that reflect differing
receptor affinities: pro-BDNF displays higher affinities for p75
NTR,
whereas mature BDNF has greater affinities for TrkB.
BDNF binds the 145 TrkB full-length receptor and a truncated
gp95TrkB variant that retains direct signaling activities [3] and
increases specificity for BDNF [3,4,5]. While the Trk receptors are
involved in most of the survival and growth properties of the
neurotrophins, the functions of p75
NTR, extensively studied in
neurons, depends on neural cell type, the presence of ligand, and
its association to a co-receptor. Indeed, p75
NTR associated with
Trk co-receptor enhances [6] or suppress neurotrophin-mediated
cell survival [7]. It was recently shown to be able to bind pro-
BDNF and induce cell death when associated with sortilin (a
member of the Vps10p-domain receptors family) [8,9,10].
Thus, regulation of pro-BDNF processing adds additional
control over the balance between p75
NTR and TrkB engagement
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25097[11,12]. The antiapoptotic function of BDNF is mediated though
interaction with the high-affinity receptors 95 and 145TrkB [5],
while pro-BDNF induces apoptosis via interaction with a receptor
complex of p75
NTR and sortilin [10,13].
Sortilin is expressed in several tissues, notably brain, spinal cord,
heart, muscle, adipocytes [14] and B lymphocytes [8]. Sortilin was
initially described in human neural cells as an intracellular
transport protein for neurotrophins and proneurotrophins [15]
and, recently, as a transporter of Trk neurotrophin receptors in
neural cells [16]. Moreover, sortilin was also known as a co
receptor (NTSR3) for a G protein-coupled receptor, the
neurotensin receptor-1 (NTSR1) that is activated by neurotensin
[17]. Neurotensin was initially shown to play a role in the growth
and survival of colorectal cancer (CRC) cells, through its binding
to this sortilin/NTSR1 complex [18].
BDNF has been implicated in the pathogenesis and prognosis of
numerous human malignancies such as neuroblastomas [19,20],
medulloblastoma [21], prostate cancer [22,23], lung cancer [24],
pancreatic carcinoma [25,26,27], and hepatocellular carcinoma
[28]. In CRC, an overexpression of BDNF [29] and TrkB [30]
was recently reported in patients’ tissues but no data deals with the
function of BDNF as an autocrine loops in CRC cell survival.
Since TrkB expression is associated to several cancers; the goal of
this study was to define the conditions of endogenous secretion of
BDNF and expression of neurotrophin receptors in CRC. Herein,
we show that endogenous BDNF is secreted by CRC cells
submitted to serum deprivation and induces cell survival through
TrkB tyrosine kinase receptor that is expressed on the membrane
of stressed cells. It is noteworthy that TrkB and BDNF expression
was enhanced in patients’ tumors especially in advanced stages.
Collectively, these data point out the relevance of BDNF/TrkB
pathway in the growth and potential invasiveness of CRC.
Materials and Methods
Cells and culture
Human CRC cell lines corresponding to different tumor stages
were purchased from the American Type Culture Collection.
WiDr [31] and SW480 [32] were primary CRC-derived cell lines,
whereas the two other lines were derived from CRC metastases, in
lymph node (SW620 deriving from the same patient as the SW480
line) [32] and ascitis (COLO 205) [33]. Under basal conditions,
WiDr cells were maintained in MEM medium (Gibco) supple-
mented with 10% heat-inactivated Fetal Calf Serum (FCS)
(Gibco), 1 mM sodium pyruvate (Gibco), 1% non essential amino
acids (Gibco), 100 IU/ml penicillin and 100 mg/ml streptomycin
(Gibco). SW480, SW620 and COLO 205 lines were cultured in
RPMI medium (Gibco) supplemented with 10% FCS, 100 IU/ml
penicillin and 100 mg/ml streptomycin, at 37uC under humidified
atmosphere and 5% CO2. Cultured cells were stressed by 24 to
72-h serum starvation. The mouse antagonistic anti-BDNF
monoclonal antibody (mAb) clone 35928.11 (10 mg/ml) was
purchased from Calbiochem. Recombinant human BDNF
(100 ng/ml), recombinant pro-BDNF (4 ng/ml), and K252a
(200 nM) were purchased from Alomone labs.
Patients and tissue samples
All patient-derived tissues were collected and archived, at the
Tumorotheque of Limoges University Hospital, under protocols
approved by the Institutional Review Board (AC N 2007-34, DC
2008-604 and 72-2011-18). Written informed consent was
obtained by all subjects for this study. Tumor tissues were
obtained from 20 patients, who underwent surgical removal of
CRC in Limoges University Hospital between January 2006 and
February 2007. Four adenocarcinoma patients per stage (accord-
ing to the pTNM classification [34]) have been chosen for this
study. Tissues from four patients with a benign colorectal disease,
megadolichocolon, were used as controls.
RT-PCR analysis
CRC cell lines were cultured in medium containing or not 10%
FCS for 24 to 72-h. SV total RNA isolation system (Promega) was
used to isolate total RNA from the cell lines as described in the
manufacturer’s instructions. The amount of RNA extracted was
quantified by measuring the absorbance at 260 nm using the
Nanodrop spectrophotometer ND-1000 (Labtech). The purity of
the RNA was checked by the ratio DO260/DO280 nm between
1.83 and 2.00. The absence of RNA degradation was confirmed
by electrophoresis on a 1.5% agarose gel containing ethidium
bromide. Extraction of RNA from patients’ tissues was performed
as described [35]. First-strand cDNA synthesis was generated by
using SuperScript III (Invitrogen). PCR was performed using Taq
DNA polymerase (Invitrogen). Total RNA isolated from human
neuroblastoma cell lines (IMR32, SH-SY5Y) and human erythro-
myeloblastoid leukemia K562 cells were used as positive controls.
Non-reverse–transcribed samples (manufactured by omitting the
reverse transcriptase) were run in parallel with the reverse-
transcribed samples to exclude contamination by genomic DNA.
Primers were designed using Primer 3 (provided in the public
domain by the Whitehead Institute for Biomedical Research/MIT
Center for Genomic Research, Cambridge, MA, and available at
http://www.wi.mit.edu). Designed primer pairs are listed, along
with their expected product size and annealing temperatures in
Table 1.
Sequencing
After extraction of PCR products with Rapid PCR Purification
Systems (MARLIGEN bioscience), according to the manufacturer’s
instructions, PCR products were directly sequenced using the
BigDyeH Terminator v1.1 Cycle Sequencing Kit (Applied Biosys-
tems) in a GeneAmpH PCRSystem 2700 thermocycler (Applied
Biosystems). The fragments were purified by isopropanol precipi-
tation. The sequencing gel was run on an automated laser
fluorescent DNA sequencer ABI PrismH 31306l Genetic Analyser
(Applied Biosystems) and homologies were checked, using Finch
TV, after blasting with the BDNF, TrkB145, TrkB95, p75
NTR,a n d
sortilin GenBank sequences (NM_001143816, NM_001018064,
NM_001007097, NM_002507, and NM_002959, respectively).
Western blot
Mouse anti-BDNF (1 mg/ml) and mouse anti-TrkB (1 mg/ml)
antibodies (Abs) were purchased from R&D Systems, rabbit anti-
P75
NTR (1 mg/ml), goat anti-sortilin (1 mg/ml) and rabbit anti-
phospho-Akt (Ser 473; 1 mg/ml) Abs from Santa Cruz Biotech-
nology, rabbit anti-TrkA (1:1000), rabbit anti-TrkC (1:1000) and
mouse anti-Akt (1:2000) Abs from Cell Signaling Technology.
Subconfluent cell lines cultures were lysed (5 minutes on ice) in the
culture flasks by 16Cell lysis buffer (Cell Signaling Technology)
containing 1 mM PMSF (Sigma-Aldrich). The suspension was
sonicated for 1 min (a pulsation of 40 Hz every 20 sec) to degrade
chromosomal DNA and centrifuged at 14,000 g for 10 minutes.
Supernatants were collected and protein concentration was
determined using Bradford protein concentration assay (Sigma).
SDS-PAGE was performed and the proteins were electro-blotted
onto PVDF membranes (BioTrace
TM). After one hour of
incubation at room temperature in blocking solution (5% non-
fat dry milk in PBS), the membranes were exposed to the specific
primary Abs in blocking solution overnight at 4uC. Then,
BDNF/TrkB and Sortilin Promote CRC Cell Survival
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20 and the immunoreactions were detected by horseradish
peroxidase-conjugated secondary Ab to mouse, rabbit, or goat Ig
(Dakocytomation) diluted at 1:2000 in blocking solution for 1 h at
room temperature. After washing, visualization of immunocom-
plexes was accomplished using the Immobilon Western Chemi-
luminescent HRP Substrate (Millipore). Protein-loading control
was performed with anti-Actin Ab (Cell Signaling Technology).
Western blots were scanned using a bio-imaging system (Genes-
nap; Genetool; Syngene). Densitometric analyses were performed
using an IMAGEJ software program (National Institutes of
Health, Bethesda, MD, USA http://rsb.info.nih.gov/ij/). Protein
expression was determined in relative units in reference to actin
expression.
Immunofluorescence
Cells grown on 12-mm coverslips were fixed with 4% PFA at
room temperature for 30 min, and permeabilized or not with
0.1% Triton X-100. Nonspecific binding was blocked by 30 min
incubation with PBS-2% BSA at room temperature. Coverslips
were then incubated overnight at 4uC in blocking solution with the
primary Ab. The following Abs were used: rabbit anti-BDNF Ab
(1 mg/ml; Santa Cruz Biotechnology), rabbit anti-pro-BDNF Ab
(8 mg/ml; Alomone Labs), mouse anti-TrkB Ab (2.5 mg/ml; R&D
Systems), rabbit anti-p75
NTR (2 mg/ml; Santa Cruz Biotechnolo-
gy) and goat anti-sortilin Ab (1 mg/ml; Santa Cruz Biotechnology).
Cells were washed 3 times in PBS, and incubated for 2 h at room
temperature with Alexa Fluor-conjugated secondary Abs (Invitro-
gen) diluted 1:5000 in PBS. After 3 washes in PBS, nuclei were
stained for 5 min with DAPI. After intensive washes, coverslips
were inverted on slides and mounted with Dako Fluorescent
Mounting Medium (Dakocytomation). Negative controls were cells
incubated with irrelevant normal rabbit, mouse, or goat IgG
(Sigma). Pictures were taken using a confocal microscope (Carl
Zeiss, LSM 510); surface plots of fluorescence data were generated
with IMAGEJ software program.
ELISA
After a 24-h, 48-h and 72-h culture, the samples of supernatant
from cell lines were collected and stored at 280uC until the day of
Table 1. Primers used in RT-PCR studies.
Name Primers sequences Amplified fragments HT (6C) 39 Location
BDNF
F TACTTTGGTTGCATGAAGGCTGCC 266 bp 58 596
R ACTTGACTACTGAGCATCACCCTG
TrkB145
F AGGGCAACCCGCCCACGGAA 571 bp 62.6 2860
R GGATCGGTCTGGGGAAAAG
TrkB95
F GTTTCATAAGATCCCACTGGA 261 bp 58 7111
R TGCTGCTTAGCTGCCTGAGAG
TrkA
F TCAACAAATGTGGACGGAGA 197 bp 58 1372
R GTGGTGAACACAGGCATCAC
TrkC
F ACTTCCGTCAGGGACACAAC 219 bp 58 1708
R CCTCCCTCTGGAAATCCTTC
p75
NTR
F GTGGGACAGAGTCTGGGTGT 200 bp 60 3109
R AAGGAGGGGAGGTGATAGGA
Sortilin
F CTGGGTTTGGCACAATCTTT 199 bp 60 1161
R CACCTTCCTCCTTGGTCAAA
Sortilin EC
F TCCTGGGTTGGAGATAGCAC 231 bp 58 392
R TTCCTCCAGACACCTCTGCT
Sortilin IC
F GCTGGTCACAGTCGTAGCAG 150 bp 58 2350
R TTAGTGTGGGAGGCTGTGTC
GAPDH
F GGGTGGAATCATATTGGAACATG 150 bp 58 2199
R GTCGGAGTCAACGGATTTGG
F, forward; R, reverse; HT, hybridation temperature.
doi:10.1371/journal.pone.0025097.t001
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performed according to the manufacturer’s instructions. Results
were expressed as mean 6 SEM (pg/mL). At least three
independent experiments were performed for each experimental
condition, each with measurements in triplicate.
Cell proliferation assays
Cell proliferation was measured using the Click-it EdU Alexa
Fluor 488 Flow cytometry assay (Invitrogen), according to the
manufacturer’s instructions. Briefly, cells (2610
5 per well) were
incubated overnight on twelve-well plates before treatment, then
cultured for 24-h in serum-free medium with or without
exogenous BDNF, K252a or both BDNF and K252a added
simultaneously. Proliferation values were measured using a BD
LSRFortessa flow cytometry (BD Biosciences). Experiments were
performed in triplicate, and three sets of 50,000 cells were
collected for every condition. The data were acquired and
analyzed by the BD FACSDiva 6.0 software (BD Biosciences).
Each experiment was repeated at least thrice.
Apoptosis assay
Apoptosis was measured by the detection of cytoplasmic soluble
nucleosomes using a calorimetric assay, Cell Death Detection
ELISAPLUS kit (Roche Molecular Diagnostic) according to the
manufacturer’s instructions. Absorbance values were measured at
405–490 nm dual wavelengths. The absorbance obtained in
controls was normalized to a value of 1, as previously described
[7]. All the experiments were performed in triplicate and repeated
at least three times.
Statistical analysis
Statistical significance was determined by a one-way analysis of
variances (ANOVA) with statview 5.0 software (Abacus Concepts).
P values,0.05 were considered significant. Mean and SEM values
were obtained from at least 3 independent experiments.
Results
ColoRectal Cancer cell lines express TrkB and p75
NTR but
not TrkA or TrkC receptors
TrkB and p75
NTR expressions were detected in CRC cell lines
under basal (10% FCS) culture conditions, both at mRNA
(Figure 1A) and protein (Figure 1D) levels with some differences
depending on cell lines. Whereas the full length TrkB (TrkB145)
and p75
NTR transcripts were predominant in a primary (SW480)
and a metastasis (SW620) line (Figure 1A) (two cell lines isolated
from the same patient), the most strongly expressed transcripts
were those of the truncated isoform (TrkB95) in all cell lines
(Figure 1A) except for WiDr cells that expressed TrkB95 and
p75
NTR only after a 48-h serum deprivation (Figure 1B). TrkB and
p75
NTR sequencing after agarose elution gels validated these
results. However, TrkA and TrkC transcripts (Figure 1C) as well as
proteins receptors (Figure 1D) were not detected, whatever culture
conditions, in contrast to the erythromyeloblastoid leukemia K562
cell line known to express these neurotrophin receptors [36].
CRC cells produce endogenous BDNF
Since CRC expressed TrkB receptors, we searched for an
endogenous production of BDNF, a TrkB ligand. BDNF mRNA
was detected in all studied cell lines under basal (10% FCS)
conditions, predominantly in the two primary CRC lines (WiDr
and SW480). Interestingly, following serum starvation for 24 to
72 h, BDNF mRNA levels (Figure 2A), as well as mature BDNF
protein (17 kDa) detected by Western blot in cell lysates, were
enhanced in the four CRC cells (Figure 2B), as shown by
densitometry values (BDNF/GAPDH ratios for mRNA and
BDNF/Actin ratios for proteins) (Figure 2A, B). In addition,
BDNF secretion was detected by ELISA in culture supernatant of
CRC cell lines. BDNF release was significantly increased by serum
starvation in the two primary WiDr and SW480 CRC cell lines
(Figure 2C and Table 2) whereas, it was no significantly enhanced
in metastatic SW620 and COLO 205 CRC cell lines (Table 3).
Serum deprivation led to an increase of BDNF levels in the
cytoplasm of these four cell lines as shown for SW480 in Figure 2D.
Quantifying the green fluorescence intensity in every culture
conditions confirmed the findings from the fluorescence images
(Figure 2D) and reinforced the results obtained by Western
blotting.
Serum starvation induces membranous expression of
TrkB and its colocalization with BDNF
The finding that endogenous BDNF is secreted under serum
starvation conditions led us to search for the expression of its high
affinity receptor. In basal (FCS-containing) cultures (Figure 3A, C),
the high affinity receptor TrkB and its ligand BDNF were
sequestered in all CRC cell lines. A 24-h serum starvation induced
a relocation of TrkB to the cell membrane (Figure 3B, D).
Interestingly, a colocalization of TrkB and BDNF on the
membrane was detected in all studied cell lines and reached a
maximum at 72 h of deprivation, as shown for WiDr and COLO
205 cells (Figure 3B, D). Similar staining patterns were obtained
for SW480 and SW620 (data not shown). The coexpression at the
membrane of both TrkB and endogenous BDNF suggests that
BDNF and TrkB could be implicated in an autocrine loop in
stressed CRC cells.
BDNF promotes proliferation and survival of CRC cell
lines through TrkB
To determine the function of this ligand-receptor system in the
proliferation and survival of WiDr, SW480, SW620 and COLO
205 CRC cells, proliferation and apoptosis assays were performed
with exogenous BDNF either in FCS-free or in 10% FCS-
containing cultures. After a 24-h culture in serum-free medium,
exogenous BDNF significantly increased the proliferation of all
studied cell lines, in contrast to the absence of effect in the
presence of 10% FCS (Figure 4A and Table 2, 3). Since TrkB was
expressed at the surface of stressed cells, we hypothesized its
possible role in the cell proliferation under such conditions.
Indeed, the addition of K252a, a Trk inhibitor [37], suppressed
the proliferative effect of exogenous BDNF in serum-free cultures
in all studied cell lines (Figure 4A) which suggests that endogenous
BDNF was implicated in cell growth through TrkB (Fig. 4A and
Table 2, 3). To further evaluate the role of TrkB and BDNF in
stressed CRC cell survival, apoptosis was evaluated by soluble
nucleosome cytoplasmic levels in cultures with and without
exogenous BDNF or K252a. After a 24-h serum starvation,
WiDr, SW480, SW620, and COLO 205 cells stimulated with
exogenous BDNF had significantly decreased apoptotic ratios,
whereas no significant effect was observed on cells maintained in
normal medium (Figure 4B, C and Table 2, 3). Moreover, 200 nM
K252a increased the apoptotic ratios of WiDr, SW480, SW620,
and COLO 205 (Figure 4B, C and Table 2, 3). The results
obtained after 48 and 72-h serum starvation confirmed these data
(Fig. 4B, C), suggesting that the proliferation of CRC cells might
be mediated by a BDNF/TrkB signaling pathway.
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TrkB activation, we searched for Akt phosphorylation in two CRC
cell lines following BDNF treatment. Indeed, western blotting
revealed that the exposure of WiDr or SW480 to BDNF after a 16-
hour serum deprivation, induced Akt phosphorylation (Ser 473)
after 5 minutes, reached maximum at 30 minutes (7 to 8-fold
increase) and yet detected after 24 hours (3 to 4-fold increase)
(Figure 5).
We therefore determined apoptotic levels of the four cell lines in
the presence of a neutralizing anti-BDNF mAb [38]. This mAb
indeed increased the apoptosis of primary CRC lines: WiDr
(Figure 4D, left and Table 2), SW480 (Figure 4D, right and
Table 2) and metastatic lines, SW620 (Figure 4E, left and Table 3)
and COLO 205 (Figure 4E, right and Table 3).
Altogether, these data suggest that endogenous BDNF is
implicated in CRC cell survival in serum-free cultures via TrkB
through an autocrine loop. This led to study the role of sortilin in
BDNF traffic.
Sortilin, a BDNF trafficking protein, is expressed by CRC
cell lines
The primers used in the study of sortilin transcripts recognized
the intracellular part of the protein (sortilin IC involved in
neurotrophin trafficking) and the extracellular part (sortilin EC
Figure 1. Expression of BDNF and its receptors in human CRC cell lines. (A): RT-PCR of BDNF, its high (TrkB) and low (p75
NTR) affinity
receptors, TrkA, and TrkC from cells cultured in basal (10% FCS medium), WiDr (lane: 1), SW480 (lane: 2), SW620 (lane: 3), COLO 205 (lane: 4). GAPDH
mRNA levels was used as an internal control. Positive control (lane 5) was the neuroblastoma cell line (IMR32) for BDNF, TrkB and p75
NTR; and the
erythromyeloblastoid leukemia cells (K562) for TrkA and C. A representative result of at least three to five independent experiments. (B) Comparison
of TrkB95 and p75
NTR on total RNA extracted from WiDr cells cultured in 10% FCS or after 24 to 72 h serum deprivation (0% FCS). TrkB95 and p75
NTR
mRNA/GAPDH mRNA quantification of band intensities evaluated by densitometry are shown above lanes and expressed in arbitrary units (mean of
three independent experiments). (C) Same experiment: RT-PCR of TrkA and TrkC on total RNA extracted from WiDr cells cultured under basal culture
conditions (10% FCS) and after 24–72 h of serum starvation in comparison to positive control (K562) (D) Expression of pro-BDNF and BDNF, full length
TrkB 145 and truncated TrkB 95 and p75
NTR proteins in CRC cell lines cultured in 10% FCS. TrkA and TrkC were not detected. Actin was used as
loading protein control. WiDr (lane: 1), SW480 (lane: 2), SW620 (lane: 3), COLO 205 (lane: 4). Positive control (lane: 5) were IMR32 cells for BDNF, pro-
BDNF, TrkB and p75
NTR and K562 cells or TrkA and TrkC. A representative result of at least three independent experiments.
doi:10.1371/journal.pone.0025097.g001
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PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e25097Figure 2. Comparison of BDNF production in CRC cells cultured with 10% or without FCS (0% FCS). (A) BDNF production assessed by RT-
PCR of total RNA extracted from cells cultured in basal condition (10% FCS) and for 24 to 72 h of serum deprivation. Quantification of band intensities is
shownas above(mean ofthree independent experiments).(B) BDNF expressionbywestern blotting(in referencetoactin) in total cellularproteinextracted
from cell lines cultured under basal condition (10% FCS) and after 24–72 h of serum deprivation (0% FCS). According to densitometric analyses,
quantification showedasignificantincreasedexpressionofBDNF inculturedcells.Histogramsaremeans6SEM of at least three independent experiments.
**, p,0.01; ***, p,0.001, in comparison with basal culture conditions. (C) Secretion of BDNF assessed by ELISA in supernatant of the WiDr and SW480 cell
lines under basal condition (10% FCS) and after 24–72 h of serum deprivation (0% FCS). Results are expressed as the mean 6SEM of triplicates from three
different experiments. ***, p,0.001, when compared with basal culture condition. (D) Comparison of BDNF expression by SW480 cells cultured in 10% FCS
and after 72-hserum deprivation. Confocal microscopy with anti-BDNF Ab and Alexa fluor-488 conjugate (green) and nuclei counter stained withthe blue-
fluorescent DNA stain DAPI. Relative quantification was assessed by green fluorescence surface plot. Images were representative for at least three
independent experiments. Scale bars, 10 mm. Similar results were observed with the three other lines (data not shown).
doi:10.1371/journal.pone.0025097.g002
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and protein (Figure 6B) were detected in all studied cell lines. By
comparison with cells cultured in 10% FCS, a 24 to 72-h serum
deprivation enhanced sortilin expression as detected on immuno-
blots of WiDr, SW480, SW620 and COLO 205 extracts
(Figure 6B). Sortilin is known to exist under two different states
of glycosylation in CRC cells. Indeed, it was detected as a doublet
in the SW480 cell line (Figure 6B), but barely in others (WiDr,
Colo205) with an expression variable between cell lines and
cultures (Figure 6B). Sortilin was detected in all CRC cell lines by
confocal microscopy also, as shown for SW620 (Figure 6C).
Double-staining for sortilin and BDNF showed a striking
colocalization with increased fluorescence intensities after 24-h
serum starvation (Figure 6C). Quantifying the green (BDNF) and
red (sortilin) fluorescence intensities in each culture conditions
confirmed the findings from the fluorescence images (Figure 6C).
Similar staining patterns were observed with WiDr, SW620, and
COLO 205 cell lines under the same conditions (data not shown).
Altogether, our results are in agreement with the hypothesis that
sortilin could exert the function of transporter for BDNF.
Pro-BDNF induces CRC cell apoptosis through activation
of a p75
NTR-sortilin receptor complex
The immature form of BDNF, pro-BDNF was also detected by
Western blotting in all CRC cell lines as a 32–34 kDa protein
doublet (Figure 1D). In addition to its role of precursor leading to
mature BDNF, a specific and opposite function is related to its
high affinity binding to p75
NTR, a death domain receptor, as
Table 2. BDNF release and effect of exogenous BDNF, pro-BDNF, TrkB inhibitor (K252a) and neutralizing anti-BDNF on apoptosis
and proliferation in primary CRC cell lines.
WiDr
BDNF Release
24 H 48 H 72 H
10% FCS 1660.98 2761.23 4561.28
0% FCS 5360.57*** 29165.03*** 23469.45***
EDU ECD
24 H 24 H 48 H 72 H
10% FCS 160.03 160.03 160.07 160.03
10%+BDNF 1.1260.04 160.06 0.9760.08 0.9860.02
0% FCS 0.4760.06 1.1960.03 1.360.02 1.3860.04
0%+BDNF 0.7560.04** 1.0160.03** 1.0760.02*** 1.0960.03**
0%+BDNF/K252a 0.00360.001*** 1.160.02* 1.460.04 1.660.07**
0%+K252a 0.01560.001*** 1.3460.02** 1.6360.04*** 1.860.05***
0%+Anti-BDNF nd 1.6260.04*** nd nd
0%+Pro-BDNF nd 1.360.02** nd nd
SW480
BDNF Release
24 H 48 H 72 H
10% FCS 1661.15 28612 8 61.2
0% FCS 8661.5*** 12161.2*** 17065.56***
EDU ECD
24 H 24 H 48 H 72 H
10% FCS 160.07 160.06 160.04 160.05
10%+BDNF 1.0960.06 1.0660.05 0.9560.08 160.01
0% FCS 0.4660.07 1.3660.05 1.2960.04 1.2460.03
0%+BDNF 0.8160.03*** 1.0460.02*** 0.9360.03*** 0.8460.05***
0%+BDNF/K252a 0.0560.006*** 1.4560.02 1.4360.07 1.4160.05*
0%+K252a 0.0460.005*** 1.7360.06*** 1.660.03** 1.7360.04***
0%+Anti-BDNF nd 1.8260.04*** nd nd
0%+Pro-BDNF nd 1.4260.02*** nd nd
Results are expressed as relative units of proliferating cells (EDU) or apoptotic ratios of soluble nucleosomes detected by ELISA Cell Death (ECD) after 24 to 72-hours (H)
of serum deprivation (0% FCS). Mean 6 SEM of at least three independent experiments.
*, p,0.05;
**, p,0.01;
***, p,0.001, compared with serum-free condition alone (0% FCS).
doi:10.1371/journal.pone.0025097.t002
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We thus examined the functional effect of exogenous pro-BDNF
on the four CRC cell lines maintained in serum-free medium.
Apoptotic ratios significantly increased in all CRC lines, especially
in the two primary lines (Figure 7D, E and Table 2, 3). We
speculated that pro-BDNF exerts pro-apoptotic activity through
the recruitment of sortilin by p75
NTR as known in neurons [10].
To address this hypothesis, we evaluated the coexpression of
sortilin and p75
NTR by confocal microscopy. As illustrated with
SW480 and SW620 lines, a clear-cut colocalization and
punctiform polarization of p75
NTR and sortilin in the cell
membrane was observed in all CRC cell lines (Figure 7A, B).
On the other hand, pro-BDNF was also colocalized with sortilin as
detected for WiDr (Figure 7C) as for the three other cell lines (data
not shown). These findings suggest that pro-BDNF and the
complex p75
NTR/sortilin could counterbalance the autocrine
survival TrkB/mature BDNF loops in CRC cell lines.
BDNF and its receptors are highly expressed in vivo
BDNF and receptor expression was evaluated by RT-PCR in
CRC samples obtained surgically from 16 patients with adeno-
carcinoma. Samples from patients with benign colorectal disease
(megadolichocolon) were studied as controls. Patients’ tumor and
adjacent non-tumor tissues were compared. BDNF and its
receptors TrkB and p75
NTR transcripts were detected at the
expected size in tissues from patients’ colonic carcinoma, whatever
TNM stage. BDNF, TrkB145, and TrkB95 expression was higher
in tumors than in non-tumor tissues from the same patient and in
Table 3. BDNF release and effect of exogenous BDNF, pro-BDNF, TrkB inhibitor (K252a) and neutralizing anti-BDNF on apoptosis
and proliferation in metastatic CRC cell lines.
SW620
BDNF Release
24 H 48 H 72 H
10% FCS 960.57 11611 5 62.5
0% FCS 1160.5 13611 7 61
EDU ECD
24 H 24 H 48 H 72 H
10% FCS 160.05 160.06 160.09 160.08
10%+BDNF 0.9460.045 1.0460.08 1.0360.08 160.08
0% FCS 0.3460.035 1.3860.03 1.3360.01 1.3460.06
0%+BDNF 0.8360.06*** 0.860.12*** 0.6760.02*** 0.5760.03***
0%+BDNF/K252a 0.1860.006* 1.760.06* 1.960.02*** 2.160.02***
0%+K252a 0.0860.012** 1.9660.06*** 2.460.05*** 2.860.09***
0%+Anti-BDNF nd 1.2860.04** nd nd
0%+Pro-BDNF nd 1.2260.02** nd nd
COLO 205
BDNF Release
24 H 48 H 72 H
10% FCS 9611 0 61.1 1060.5
0% FCS 10611 1 60.5 1560.4
EDU ECD
24 H 24 H 48 H 72 H
10% FCS 160.088 160.06 160.03 160.04
10%+BDNF 0.8660.03 160.07 160.03 160.05
0% FCS 0.360.012 1.0860.04 1.0860.002 1.0260.007
0%+BDNF 0.6460.016*** 0.660.04*** 0.7360.01*** 0.6860.03***
0%+BDNF/K252a 0.3860.012* 1.2460.05* 1.860.03*** 1.860.04***
0%+K252a 0.1760.01*** 1.6560.04*** 2.560.1*** 2.360.06***
0%+Anti-BDNF nd 1.2260.03** nd nd
0%+Pro-BDNF nd 1.360.04** nd nd
Results are expressed as relative units of proliferating cells (EDU) or apoptotic ratios of soluble nucleosomes detected by ELISA Cell Death (ECD) after 24 to 72 hours (H)
of serum deprivation (0% FCS). Mean 6 SEM of at least three independent experiments.
*, p,0.05;
**, p,0.01;
***, p,0.001, compared with serum-free condition alone (0% FCS).
doi:10.1371/journal.pone.0025097.t003
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Noteworthy, BDNF, TrkB95 and TrkB145 expressions were
higher in the advanced CRC stages. In contrast, the expression of
p75
NTR was lower in tumor samples than in their non-tumor
counterparts (Figure 8D). These preliminary data are in
accordance with our findings with the cell lines, pointing-to the
activation of the BDNF/TrkB machinery in CRC tissues and its
likely critical role in tumor growth.
Discussion
The present data provide evidence that endogenous BDNF is an
essential autocrine factor able to rescue human CRC cell death
under stressed culture conditions through TrkB, its tyrosine kinase
receptor. High BDNF expression was reported in neuroblastoma
[39,40], myeloma [41], B-lymphocytic leukemia cell lines [8],
bladder cancer [42], choriocarcinoma [43] or pancreatic cancer
[26]. The role of TrkB in tumor invasiveness was first identified in
neuroblastoma [39,40] and its expression is associated with a poor
prognosis [40,44]. Several recent reports focused on TrkB
overexpression in various cancers such as ovarian [45], head
and neck [46], lung [47], hepatocellular [48], pancreas [49] and
bladder carcinomas [42]. Numerous mechanisms underlying TrkB
oncogenic function were hypothesized [50]. They were based on
epithelial-to-mesenchymal transition in invasive tumors [46,51,52]
and resistance to anoikis [51,52,53]. In addition, BDNF is
upregulated by hypoxia through HIF-1a and promotes angiogen-
esis [19], as described in neuroblastoma models. However, BDNF
and TrkB functions in CRC remain unclear despite two studies
describing an overexpression of TrkB [29,30] in CRC tumors.
Herein, we provide evidences that an autocrine secretion of BDNF
is enhanced by stress culture condition that induces in parallel the
relocation of TrkB receptor at the membrane. This mechanism
seems to be of major importance in the cancer cell survival
through a fine-tuning role of CRC cell growth, as deduced from
the proliferative and anti-apoptotic functions of BDNF. It was
reported that the BDNF/TrkB pathway promotes cell survival and
Figure 3. Membranous and cytoplasmic expression of BDNF and TrkB depending on culture conditions. Confocal microscopy of WiDr
(A, B) and COLO 205 (C, D) cells, stained with an anti-BDNF Ab (red), anti-TrkB mAb (green) or both (overlay) cultured with 10% FCS (A, C) or after 24-h
serum deprivation (B, D). Under basal culture conditions (10% FCS), TrkB and BDNF were sequestered in the cytoplasm (arrows) in WiDr (A) and COLO
205 (C) cells. The same staining patterns were obtained with the two other cell lines (data not shown). After serum starvation relocation to the cell
membrane and colocalization of TrkB and BDNF (yellow in merged, arrows) were detected in WiDr (B) and COLO 205 (D). Images were representative
for at least three to five independent experiments.
doi:10.1371/journal.pone.0025097.g003
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[54,55]. BDNF increases the proliferation of TrkB-expressing
SY5Y neuroblastoma cells, whereas it has no effect on the cells
without TrkB expression [39]. BDNF has been shown to enhance
the survival of both myeloma [41,56,57] and B-cell lines after
serum deprivation [8,58] whereas, anti-BDNF Ab decreased
tumor growth in myeloma and neuroblastoma models [57,59].
Likewise, experiments using blocking anti-BDNF mAb enhanced
CRC cell death, since exogenous BDNF increased cell growth and
decreased apoptotic ratios of CRC cells in serum-free condition. It
was previously shown that BDNF triggers several survival signaling
pathways such as PI3-kinase/Akt in neuroblastoma cell lines [60]
as well as in embryonic cortical neurons from rats [61]. However,
different biological effects induced by BDNF activation were
described. Whereas BDNF stimulated the differentiation of normal
neural stem cells during brain development depending on
neuronal NO synthase activity [62], a proliferative effect was
achieved on several tumor cells such as ovarian [63], neuroblas-
toma [39], myeloma and malignant human B cell lines [41,56,57].
By contrast to normal embryonic neural stem cells, such
differences in BDNF properties in tumor cells could be a hallmark
of tumor invasiveness.
BDNF is synthesized by neurons as pro-BDNF that is cleaved by
matrix metalloproteases (MMP), especially MMP-7 and MMP-9
[2] to produce the mature form of BDNF. This process was not
previously reported in CRC cells. Interestingly, the expression of
these MMP was reported in CRC patients’ tissues [64] suggesting
that these MMP could be implicated in the cleavage of pro-BDNF
in CRC cells.
That BDNF is secreted in association with sortilin, especially
under stress conditions, was not previously described in CRC cells.
Sortilin was initially known to regulate neurotrophin traffic in
human neuronal cells [15] and B lymphocytes [8]. It has been
shown in human neuronal cells that sortilin plays a key role in the
intracellular transport of neurotrophins and proneurotrophins,
which leads to axonal growth and neural cells proliferation
[1,15,65,66]. When p75
NTR signals independently of Trk, it
requires sortilin as a coreceptor, then binds pro-BDNF and
induces apoptosis [9,10,67,68]. The present results point for a dual
function of sortilin in CRC, the induction of survival, through its
trafficking and secretion of mature BDNF and a proapoptotic
function through its p75
NTR-sortilin complex bound to pro-
BDNF. Therefore, the role of sortilin seems to be a complex
balance between these two opposite functions. Shedding of the
luminal domain of sortilin as described in HT29 cells [18] could be
another way for CRC cells to prevent the apoptotic effect of pro-
BDNF.
Previous reports have shown that the BDNF/TrkB pathway
promotes tumorigenesis, invasiveness, angiogenesis and drug
resistance, contributing significantly to the aggressive phenotype
of these poor prognosis tumors. Thus, an evaluation of BDNF/
TrkB expression in patients with CRC disease may be helpful for a
better prediction of the prognosis and treatment outcome. In the
present study, we showed that BDNF and TrkB (both forms) were
overexpressed in tumor tissue in comparison either to each
corresponding non-tumor tissue from the same patient or to the
control tissues with benign disease. In addition, it was reported
that the low affinity receptor p75
NTR acts as a tumor suppressor in
neuroblastoma cell in vivo [69], and low p75-expressing
neuroblasts were detected in primary poorly differentiated
neuroblastomas [70]. Our observation concerning the decrease
of p75
NTR receptor in tumor was consistent with these findings.
Figure 4. BDNF-TrkB promotes the cell survival of CRC cell lines. (A) Role of endogenous BDNF and its receptor TrkB on CRC cell proliferation:
effects of exogenous BDNF and suppressing endogenous TrkB receptor on cell proliferation. The four cell lines were cultured for 24 h in FCS-free
medium (FCS 10%, 2) in the presence of exogenous BDNF (+), K252a (+) alone or in combination. Cell proliferation was determined by flow
cytometry analysis using EdU Alexa Fluor 488. The data are presented as histograms of proliferating cells in relative units 6 SEM of five independent
experiments. *, p,0.05; **, p,0.01; ***, p,0.001, when compared with serum-free medium. (B, C) Effects of exogenous BDNF and suppressing
endogenous TrkB receptor on cell survival. Apoptotic ratios of soluble nucleosomes were detected by ELISA Cell for WiDr, SW480, SW620, and COLO
205 induced by serum deprivation alone (FCS 10%, 2) or in association either with exogenous BDNF (+), or with K252a (+), during 24–72 h of serum
deprivation. Histograms, mean ratio of apoptotic cells 6 SEM of at least three independent experiments. *, p,0.05; **, p,0.01; ***, p,0.001, when
compared with serum-free condition alone. (D, E) apoptotic ratio after 24 h serum deprivation alone (0% FCS) or with combination with a neutralizing
anti-BDNF mAb (0% anti-BDNF). Histograms, mean ratio of apoptotic cells 6 SEM of three independent experiments. *, p,0.05; **, p,0.01;
***, p,0.001, when compared with serum-free condition alone.
doi:10.1371/journal.pone.0025097.g004
Figure 5. BDNF triggers phosphorylation of Akt in serum-starved CRC cell lines. The ability of BDNF to activate PI3-kinase/Akt signaling
pathway in CRC cells was assessed using antibodies specific to Akt and phospho-Akt (pAkt). WiDr and SW480 cells were serum starved for 16 h. The
cells were then exposed to BDNF (100 ng/ml) and harvested at different times, for 5 minutes (min) to 24 hours (h). Thirty mg of protein lysates was
analyzed for pAkt (Ser473) and total Akt by western blot analysis. The density of each pAkt band was corrected for variance in loading, using the
density of the corresponding total Akt. The fold induction was evaluated as the ratio of phosphorylated Akt protein densities between control (0 min)
and treated cells. A representative result of at least three independent experiments.
doi:10.1371/journal.pone.0025097.g005
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PLoS ONE | www.plosone.org 12 September 2011 | Volume 6 | Issue 9 | e25097Figure 6. Sortilin expression by CRC cell lines. (A) Sortilin detection by RT-PCR of total RNA extracted from cells cultured in 10% FCS and after
24–72 h serum starvation. Expression was controlled with specific primers for its extracellular (Sortilin EC) and intracellular (Sortilin IC) parts. A
Representative result from at least three independent experiments. (B) Assessment by western blotting of sortilin expression (in reference to actin) in
total cellular protein extracted from studied cell lines cultured under basal condition and after 24–72 h of serum deprivation. According to
densitometric analyses, quantification showed a significant increased expression of sortilin in cultured cells. Histograms are means 6 SEM of at least
three independent experiments. *, p,0.05; **, p,0.01; ***, p,0.001, when compared with basal culture condition (10% FCS). (C) Confocal microscopy
of SW620 cells stained with an anti-BDNF Ab (green) and an anti-Sortilin Ab (red) and double staining (merged) in basal culture condition and after
24 h serum starvation. Relative quantification was assessed by green and red fluorescence surface plot. Images were representative for at least three
independent experiments. Scale bars, 10 mm. Similar results were observed with the three other lines (data not shown).
doi:10.1371/journal.pone.0025097.g006
Figure 7. Relationship between pro-BDNF, sortilin, p75
NTR and apoptosis. (A, B) Sortilin as a coreceptor of p75
NTR. Double staining (yellow)
of sortilin (red) and p75
NTR (green) in SW480 cells (A) and SW620 (B) after 24 h of serum deprivation. (C) Colocalization of pro-BDNF and sortilin.
Confocal microscopy study of a WiDr cells stained with an anti-pro-BDNF Ab (green) and an anti-sortilin Ab (red), and double staining (yellow) after
24 h of serum deprivation. (D, E) apoptotic ratios after 24 h serum deprivation alone (0% FCS) or combined with recombinant Pro-BDNF (0% Pro-
BDNF). Histograms, mean ratio of apoptotic cells 6 SEM of three independent experiments. *, p,0.05; **, p,0.01; ***, p,0.001, when compared with
serum-free condition alone (0% FCS).
doi:10.1371/journal.pone.0025097.g007
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PLoS ONE | www.plosone.org 13 September 2011 | Volume 6 | Issue 9 | e25097Our results suggest that BDNF and its receptors may have a
crucial function in facilitating tumorigenesis and progression of
CRC tumors.
Taken together, all these findings strongly support that
autocrine BDNF/TrkB signaling contributes to tumor cell survival
in CRC in vitro and in vivo. We also speculate that sortilin, as a
transport protein as well as a potential pro-BDNF receptor,
appears to be the key actor of this autocrine loop. Future
therapeutic strategies involving BDNF/TrkB and sortilin could be
developed from such results to improve targeted treatment of
CRC patients.
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